A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

Status Recruiting

Clinical Trial Summary

It is a single-center, open-labeled, single-arm, non-randomized, investigator-initiated trial aiming to evaluate the efficacy and safety of anti-CD19 CAR-T manufactured by OlyCAR platform (OlyCAR-019) for CD19+ refractory/relapsed B-Cell malignancies.

Clinical Trial Description

OlyCAR is a novel CAR-T manufacturing system which allows to generate clinical-use CAR-T cells in short time. This study is going to evaluate the feasibility of CAR-T manufactured by OlyCAR platform in the treatment of B-Cell malignancies. The OlyCAR-019 cells will be infused by vein. Subjects will be followed for safety and efficacy up to 12 weeks. For those with a durable remission 12 weeks after infusion, the follow-up will last for at least 12 months for disease control. ;

Study Design

Related Conditions & MeSH terms

B-Cell Leukemia
B-Cell Lymphoma
Leukemia, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trial Details

NCT number	NCT05932173
Study type	Interventional
Source	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Contact	Sanbin Wang, Professor
Phone	13187424131
Email	Sanbin1011@163.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	July 1, 2023
Completion date	June 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05365659` - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas	Phase 1
Withdrawn	`NCT05929716` - An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma	Phase 2
Active, not recruiting	`NCT05024045` - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers	Phase 1
Recruiting	`NCT05016947` - Venetoclax Plus Inotuzumab for B-ALL	Phase 1
Completed	`NCT02900716` - Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas	Phase 1
Completed	`NCT03068416` - CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy	Phase 2
Not yet recruiting	`NCT05014100` - Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma	Phase 2
Recruiting	`NCT05934838` - A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas	Phase 1
Terminated	`NCT04023071` - FT516 in Subjects With Advanced Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT04148430` - A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy	Phase 2
Completed	`NCT02933320` - BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia	Phase 1/Phase 2
Active, not recruiting	`NCT03133221` - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation	Phase 2
Completed	`NCT02741388` - A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP	Phase 1
Completed	`NCT02300402` - Detection and Characterization of Residual Masses in Lymphomas
Terminated	`NCT02266147` - Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma	Phase 1/Phase 2
Terminated	`NCT00906841` - Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma	Phase 2
Completed	`NCT00338494` - Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma	Phase 1
Recruiting	`NCT05487651` - Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies	Phase 1
Withdrawn	`NCT05570188` - Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT03281551` - Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma	Phase 1